Stocks Look Shaky, But This Sector is Booming (Biotech)

The article notes a strong 2024 YTD market rally led by semiconductors tied to the AI boom (SOXX more than doubled from April to end-June), but warns the next 1–2 months could be choppy as gains are digested. It highlights biotech outperformance: XLV hit new record highs and XBI is near 2021 peak levels, with specific momentum stories including Illumina up ~46% YTD after a prior ~80% drawdown (shares near a new 52-week high), PTC Therapeutics up ~75% since its July 2025 Sephience approval on ~36% sequential growth to $125M, and Fortrea rebounding from ~$4 to the mid-teens with Q1 revenue ~$636M flat and backlog rising to $7.8B.

Analysis

The near-term setup looks less like a clean “AI is over” call and more like a crowded-factor unwind. When leadership has been this narrow, even a modest pause in semis can create index-level volatility because passive and systematic flows are implicitly long the same names; that makes the next 4-8 weeks more about position management than fundamentals. The risk is not an outright collapse in AI spending, but a multiple reset if hyperscaler capex commentary stops accelerating.

Healthcare breadth is the more important signal. The market is rotating toward a part of the tape where earnings revisions are improving without requiring heroic assumptions, which is usually a better setup than late-cycle momentum in software or chips. Among the names here, EXEL is the highest-quality compounder, PTCT is the highest-beta launch story, and FTRE is the most fragile because turnaround equity needs both backlog conversion and margin discipline to stay intact.

The contrarian point is that XBI near prior-peak territory is already pricing in a lot of optimism, while ILMN’s recovery still depends on a sustained re-acceleration in industry spending that has not yet been fully proven. If biotech leadership broadens, the second-order winners are likely the tools and services layer—sequencing, CROs, and enabling platforms—rather than the highest-multiple single-product stories. Falsifiers: renewed AI capex upside from MSFT/GOOGL/AMZN/META/ORCL, or any biotech clinical/FDA disappointment that hits the group’s fragile confidence.

Key Decisions for Investors

• Add EXEL on pullbacks over the next 1-3 months; it screens as the cleanest risk/reward in the group with profitable growth and a lower multiple, making it the best way to express continued biotech leadership.
• Take a tactical long PTCT, but size smaller than EXEL; this is a 1-2 quarter momentum trade only. The upside is substantial if Sephience keeps outperforming, but the single-product concentration makes the thesis highly path-dependent.
• Use XBI/XLV as a relative long versus SOXX/NVDA for the next 4-8 weeks to express factor rotation away from crowded AI leadership; cut the trade if semis regain clear earnings-revision leadership or hyperscaler capex guidance re-accelerates.
• Do not chase ILMN after the rebound; wait for either a 10-15% pullback or another upward revision cycle before adding. The business can work, but the multiple already discounts a fair amount of recovery.
• Treat FTRE as a watch item rather than a high-conviction long until backlog converts into visible revenue acceleration; any evidence of slower bookings-to-revenue conversion would be the first place to fade the turnaround.